Article Details
Retrieved on: 2021-04-26 06:33:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca said on Monday that the phase 3 trial for 'nirsevimab' met its primary endpoint of a statistically significant reduction in the incidence of ...
Article found on: www.sharecast.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here